The Future of Gene Patents: Patenting DNA and Other Biological Molecules and Products Following the Supreme Court’s Decision in AMP v. Myriad Genetics.
BIOTECHNOLOGY/ FOOD AND DRUG Overcoming Barriers To Protection Of New Technologies AIPLA October 25, 2013 3:30-5:30 p.m.
Staying Current in The World of Patent Litigation: A Year (And More) In Review ABA IPL Spring Conference Friday, April 4, 2014 (10:15-11:45 am)
Patent Eligibility in Europe Colo(u)ring the Gre/ay Areas Ilya Kazi and Andrew Bentham On behalf of International Liaison Committee Supporting logos to.
Disembodied Embodiments: Medical Device Strategy for PCT and Foreign Applications Bruce D. Sunstein Sunstein Kann Murphy & Timbers LLP Boston .
35 U.S.C. §101 November 2, 2015 Stephen G. Kunin [email protected] Michael L. Kiklis [email protected] Copyright © 2015 Oblon, McClelland, Maier & Neustadt,
D RUG P ATENTING AND ITS E FFECTS ON P HARMACEUTICAL F IRMS With an Emphasis on the Gleevec Patent Case.
Myriad, Metabolite, Bilski, and Prometheus: The Four Horsemen of the Biotech Apocalypse?
